Blair said the criticism of his group's conclusion was not surprising given the widespread use of glyphosate. "These sorts of things are going to go on as evidence is evaluated and scrutinized. That is what science is in democracy."
For the new study, the authors used interviews of 2,178 people diagnosed with a lymphoma and of 2,457 similar people without the cancer between 1998 and 2004 in Spain, France, Germany, Italy, Ireland and the Czech Republic. Participants listed all of their full-time jobs that had lasted for at least one year.
Those in the high-fitness group were less than half as likely to be diagnosed with lung cancer as those in the lowest-fitness group, and the difference was similar for colorectal cancer. The researchers did not find a link between fitness and prostate cancer risk.
The ads, which will begin running in print publications and radio on Monday, feature a 35-year-old named Kristy who tried using e-cigarettes to quit smoking, but wound up using both products. She suffered a collapsed lung and was diagnosed with COPD, a chronic lung disease, before quitting altogether.
After doing an initial phone survey of more than 10,000 people between April 2012 and March 2014, the researchers followed up with about 5,000 smokers to see how they felt about the packages after one month of use.
In addition to being able to detect many more cancers and pre-cancers, the pilot of FIT in 40,000 people in the northwest, midlands and the south of England showed almost double the uptake with FIT than with the current test (guaiac faecal occult blood test or gFOBt) for those who had previously chosen not to participate (14.5 per cent climbed to 25.6 per cent).
This column discusses recent research into the relationship between inflation-adjusted launch prices and survival benefits and approval year for 58 anticancer drugs approved in the US between 1995 and 2013. The authors find that launch prices are going up by $8,500 per year, approximately 12% year over year.
Drug supply and pricing is often fixed through deals between governments and drugmakers that are "generally rather opaque", making it difficult to achieve the transparency needed to help reduce prices.
Ongoing studies are attempting to understand the variations in patterns of cancer incidence across the United States, but the wide range of factors at work – and the fact that Americans tend to move frequently – make this field a challenging one.
In any case, the barriers to participation remain legion. First of all, you need a Ph.D. to interpret the listings on the Internet. No, forget that: I have a Ph.D. and couldn’t do it. The data on ClinicalTrials.gov are daunting.
In an attempt to limit submission of fake peer reviewers, BMC has turned off the automated system that let authors provide contact information for potential reviewers, which we tapped in our Nature story as a major contributor to the problem. Authors will still be able to suggest reviewers in their cover letters.
“It's wonderful that Springer has moved to eliminate articles generated by software that intentionally produces nonsense, but what about unintentionally nonsensical articles produced by human authors?”
Now here’s the part that bothers me. We know from her last surgery that Jolie is into a fair amount of woo. Her surgeon, after all, used a homeopathic concoction claimed to improve wound healing and had her surgery done at the Pink Lotus Breast Center, which, as I noted before, is highly into “holistic” bunkum. In her latest editorial, Jolie pulls the same thing.